The Development Of Humanized Antibodies

In recent years, the global monoclonal antibody market has maintained an overall growth trend year by year, with sales revenue of 49.7 billion US dollars in 2011, 106 billion US dollars in 2017, and a compound growth rate of 11.5% in 2011-2017.

As far as the number of monoclonal antibodies (mAB) is concerned, by the end of 2017, since the first mAB was listed in 1986, 73 mAB have been approved worldwide, and 62 have been listed since 2000. To know about custom mouse monoclonal antibody production service you can search for online suppliers.

The number of mAB on the market has increased significantly in recent years, reaching 10 in 2017, the largest in recent years. In addition, in the field of non-tumor treatment, the success rate of new monoclonal antibody drugs is as high as 19.3%.

Although in general, about 80%-85% of the monoclonal antibody drugs will be in the clinical development stage, the success stories in the industry are enough to show the potential of these drugs.

In the early days, the new monoclonal antibody was derived from the immunization of mice – this is the case with the first approved monoclonal antibody, the Muromonab-CD3.

Since these antibody proteins are "heterologous", they are highly immunogenic.

Therefore, when these mAB enter the human body, they will induce the body to produce antibodies against these antibodies (human anti-mouse antibodies).

The newly raised antibodies in these humans neutralize the mAB and render them ineffective. Therefore, since the 1980s, attempts have been made to increase the proportion of sequences derived from humans in antibody sequences in an attempt to reduce the immunogenicity of these monoclonal antibodies.

Under this concept, "chimeric antibodies " have been developed, namely antibodies comprising the mouse antibody variable region and the human antibody constant region.